Table 3 Baseline characteristics of participants according to type of outcome assessment
Photograph | Blinded assessment at site | Patient self-report | |
|---|---|---|---|
(N = 159) | (N = 210) | (N = 202) | |
Age (years) | |||
N, Mean (SD) | 158, 30.8 (16.6) | 209, 30.7 (16.4) | 200, 30.9 (16.7) |
Median (min, max) | 24.5 (12.0, 75.3) | 24.2 (12.0, 75.3) | 24.3 (12.0, 75.3) |
Missing | 1 | 1 | 2 |
Gender | |||
Female (%) | 109 (69.0) | 140 (67.0) | 136 (68.0) |
Male (%) | 49 (31.0) | 69 (33.0) | 64 (32.0) |
Missing | 1 | 1 | 2 |
Type of verrucae | |||
Mosaic, n (%) | 36 (23.4) | 42 (20.6) | 46 (23.4) |
Non-mosaic, n (%) | 118 (76.6) | 162 (79.4) | 151 (76.7) |
Missing | 4 | 6 | 5 |
Duration of verrucae (months) | |||
N, Mean (SD) | 149, 29.5 (26.7) | 199, 26.9 (25.2) | 192, 26.9 (25.5) |
Median (min, max) | 24 (1, 144) | 18 (1, 144) | 19.1 (1, 144) |
Missing | 10 | 11 | 10 |
Number of verrucae at baseline | |||
N, Mean (SD) | 152, 4.0 (5.9) | 201, 3.8 (5.5) | 194, 3.9 (5.5) |
Median (min, max) | 2 (1, 55) | 2 (1, 55) | 2 (1, 55) |
Missing | 7 | 9 | 8 |
Previous treatment | |||
Yes, n (%) | 130 (82.3) | 163 (78.0) | 161 (80.5) |
No, n (%) | 28 (17.7) | 46 (22.0) | 39 (19.5) |
Missing | 1 | 1 | 2 |
Type of previous treatmenta | |||
Self-treatment, n (%) | 113 (86.9) | 144 (88.3) | 141 (87.6) |
Podiatrist/chiropodist, n (%) | 41 (31.5) | 47 (28.8) | 43 (26.7) |
GP, n (%) | 56 (43.1) | 65 (40.0) | 64 (39.8) |
Trial investigating verruca treatments, n (%) | 2 (1.5) | 2 (1.2) | 2 (1.2) |
Other, n (%) | 12 (9.2) | 14 (8.6) | 14 (8.7) |